<code id='FABD38E8B9'></code><style id='FABD38E8B9'></style>
    • <acronym id='FABD38E8B9'></acronym>
      <center id='FABD38E8B9'><center id='FABD38E8B9'><tfoot id='FABD38E8B9'></tfoot></center><abbr id='FABD38E8B9'><dir id='FABD38E8B9'><tfoot id='FABD38E8B9'></tfoot><noframes id='FABD38E8B9'>

    • <optgroup id='FABD38E8B9'><strike id='FABD38E8B9'><sup id='FABD38E8B9'></sup></strike><code id='FABD38E8B9'></code></optgroup>
        1. <b id='FABD38E8B9'><label id='FABD38E8B9'><select id='FABD38E8B9'><dt id='FABD38E8B9'><span id='FABD38E8B9'></span></dt></select></label></b><u id='FABD38E8B9'></u>
          <i id='FABD38E8B9'><strike id='FABD38E8B9'><tt id='FABD38E8B9'><pre id='FABD38E8B9'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:534
          Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT
          Adobe

          The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

          As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

          advertisement

          The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Adam's Biotech Scorecard: Do Sarepta's exon
          Adam's Biotech Scorecard: Do Sarepta's exon

          ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          As a primary care physician, here's how I hope to partner with AI

          AdobeIambothexcitedandterrifiedbytheentranceofartificialintelligenceintomyprimarycarepractice.AI’sen